Exagen Inc. (NASDAQ:XGN) Short Interest Update

Exagen Inc. (NASDAQ:XGN) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 78,100 shares, a growth of 36.5% from the November 30th total of 57,200 shares. Based on an average daily volume of 82,200 shares, the short-interest ratio is currently 1.0 days. Currently, 0.9% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

Separately, William Blair reaffirmed an “outperform” rating on shares of Exagen in a research note on Wednesday, November 13th.

Insider Buying and Selling at Exagen

In other news, CEO John Aballi acquired 24,305 shares of Exagen stock in a transaction that occurred on Thursday, November 14th. The stock was purchased at an average price of $2.81 per share, for a total transaction of $68,297.05. Following the completion of the transaction, the chief executive officer now directly owns 689,799 shares in the company, valued at approximately $1,938,335.19. This trade represents a 3.65 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Nmsic Co-Investment Fund, L.P. sold 200,000 shares of the company’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $3.30, for a total value of $660,000.00. Following the transaction, the insider now directly owns 2,108,958 shares in the company, valued at $6,959,561.40. This represents a 8.66 % decrease in their position. The disclosure for this sale can be found here. 26.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Exagen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC grew its holdings in shares of Exagen by 49.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock worth $1,651,000 after purchasing an additional 175,701 shares during the period. Verus Capital Partners LLC acquired a new stake in shares of Exagen in the third quarter worth $39,000. Palumbo Wealth Management LLC raised its stake in shares of Exagen by 14.5% in the 3rd quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company’s stock valued at $236,000 after acquiring an additional 9,695 shares during the period. Creative Planning acquired a new position in shares of Exagen during the 3rd quarter valued at $110,000. Finally, Renaissance Technologies LLC boosted its position in Exagen by 93.3% during the 2nd quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock worth $172,000 after purchasing an additional 45,476 shares during the period. 75.25% of the stock is currently owned by institutional investors and hedge funds.

Exagen Trading Down 6.5 %

Exagen stock opened at $4.71 on Monday. The stock has a market cap of $83.07 million, a PE ratio of -5.01 and a beta of 1.49. The company has a current ratio of 4.05, a quick ratio of 4.05 and a debt-to-equity ratio of 1.54. The stock has a 50-day moving average price of $3.84 and a 200 day moving average price of $2.99. Exagen has a 52 week low of $1.30 and a 52 week high of $6.22.

Exagen (NASDAQ:XGN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The business had revenue of $12.51 million during the quarter, compared to the consensus estimate of $13.55 million. During the same period in the previous year, the firm posted ($0.31) earnings per share. Equities research analysts predict that Exagen will post -0.87 earnings per share for the current fiscal year.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).